Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 12:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 7,030 matching trials from the live ClinicalTrials.gov search.
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of RO7890597 in Healthy Adult Volunteers

NCT07797478
Conditions
Healthy Volunteers
Interventions
RO7890597, Placebo, Rabeprazole, Itraconazole
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
139 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Lenexa, Kansas
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety Study of ARRY-502 in Healthy Subjects

NCT01349725
Conditions
Healthy
Interventions
ARRY-502, Placebo
Drug
Lead sponsor
Array Biopharma, now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Madison, Wisconsin
Completed Not applicable Interventional Accepts healthy volunteers Results available

Alpha as a Predictive Biomarker

NCT02796625
Conditions
Pain
Interventions
Painful Stimuli
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
21 Years to 44 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Systemic Amyloidosis
Interventions
99mTc-p5+14 is an amyloid reactive peptide labeled with technetium-99m., 99mTc-Pyrophosphate
Drug
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Knoxville, Tennessee
Conditions
Systemic Lupus Erythematosus
Interventions
GSK2586184 standard formulation, Simvastatin, Rosuvastatin, GSK2586184 new formulation
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Moderate Hepatic Impairment
Interventions
Pexidartinib
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Conditions
Pharmacokinetics
Interventions
Fostamatinib - 1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference), Fostamatinib - 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed, Fostamatinib - 1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A), Fostamatinib - 1 x 150mg mannitol based 38% drug loaded tablet (batch variant B), Ranitidine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Asthma, COPD, Interstitial Lung Disease, Cystic Fibrosis, Pulmonary Hypertension, Pulmonary Infection, Other Lung Disease
Interventions
Hyperpolarized Xe129
Drug
Lead sponsor
Mario Castro, MD, MPH
Other
Eligibility
3 Years and older
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Renal Insufficiency, Chronic, Hepatic Insufficiency, Healthy
Interventions
Sporanox, Diclofenac Sodium
Drug
Lead sponsor
Javelin Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
3
States / cities
Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee
Completed No phase listed Observational Accepts healthy volunteers

Salivary Evaluation in Healthy Volunteers

NCT00001390
Conditions
Healthy, Salivary Gland Disease
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years to 70 Years
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1993 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 1 Interventional Accepts healthy volunteers

A Midazolam Drug Interaction Study With PF-04171327

NCT00987038
Conditions
Healthy Volunteers
Interventions
PF-04171327 25 mg, Midazolam 2 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Marburg Hemorrhagic Fever
Interventions
AVI-6003, Placebo
Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Cypress, California
Conditions
Schizophrenia
Interventions
MK-8189, Placebo, Background AAP Therapy
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Glendale, California
Completed Phase 1 Interventional Accepts healthy volunteers

ZD03 Capsule Study

NCT04693455
Conditions
Healthy
Interventions
ZD03, Placebo
Drug · Other
Lead sponsor
Shanxi Zhendong Leading Biotechnology Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Completed No phase listed Observational Accepts healthy volunteers

Long-Term Motor Learning in Focal Hand Dystonia

NCT00325091
Conditions
Focal Hand Dystonia
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Completed No phase listed Observational Accepts healthy volunteers

Gait Training and Brain Changes in Stroke Patients

NCT00334230
Conditions
Gait Training, Locomotion
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 80 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in Healthy Women

NCT00869960
Conditions
Healthy
Interventions
tenofovir, emtricitabine, atazanavir, ritonavir
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years to 40 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating IMA-026 in Healthy Subjects

NCT00517348
Conditions
Healthy
Interventions
IMA-026
Biological
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Antonio, Texas
Completed No phase listed Observational Accepts healthy volunteers

An Observational Study of Lumosity in Seniors

NCT02614755
Conditions
Healthy Volunteers
Interventions
Not listed
Lead sponsor
Lumos Labs, Inc.
Industry
Eligibility
55 Years and older
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Francisco, California
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Long-Acting Local Anesthetic

NCT01786655
Conditions
Safety of Neosaxitoxin in Healthy Volunteers
Interventions
Neosaxitoxin in saline, NeoSTX + bupivacaine 0.2%, NeoSTX + bupivacaine 0.2% + epinephrine 5mcg/ml, Saline placebo
Drug · Other
Lead sponsor
Charles Berde
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Intracranial Central Nervous System Disorder, Mental Disorder, Healthy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
6 Years to 90 Years
Enrollment
949 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Alzheimer Disease, Healthy
Interventions
LY3372993, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
139 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
10
States / cities
Cypress, California • Long Beach, California • DeLand, Florida + 6 more
Conditions
Primary Sclerosing Cholangitis (PSC)
Interventions
CS0159
Drug
Lead sponsor
Cascade Pharmaceuticals, Inc
Other
Eligibility
18 Years to 55 Years
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Daytona Beach, Florida
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pantoprazole Sodium 40 mg DR Tablets Under Fasting Conditions

NCT00835588
Conditions
Healthy
Interventions
Pantoprazole Sodium 40 mg delayed-release tablets, PROTONIX® 40 mg delayed-release tablets.
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
2
States / cities
Saint Charles, Missouri • Houston, Texas